395 related articles for article (PubMed ID: 36031160)
21. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
Kile M; Sudchada P
Int Urol Nephrol; 2021 Feb; 53(2):283-290. PubMed ID: 32770437
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
Wish JB; Eckardt KU; Kovesdy CP; Fishbane S; Spinowitz BS; Berns JS
Am J Kidney Dis; 2021 Nov; 78(5):709-718. PubMed ID: 34332007
[TBL] [Abstract][Full Text] [Related]
23. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
25. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
[TBL] [Abstract][Full Text] [Related]
27. Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study.
Wang Y; Yu X
Kidney Dis (Basel); 2024 Apr; 10(2):132-142. PubMed ID: 38659701
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
[TBL] [Abstract][Full Text] [Related]
29. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
Doggrell SA
Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
[TBL] [Abstract][Full Text] [Related]
30. Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease.
Locatelli F; Del Vecchio L; Esposito C; Gesualdo L; Grandaliano G; Ravera M; ; Minutolo R
J Nephrol; 2024 Apr; 37(3):753-767. PubMed ID: 38705934
[TBL] [Abstract][Full Text] [Related]
31. [Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?].
Rawee P; Eisenga MF
Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823872
[TBL] [Abstract][Full Text] [Related]
32. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
Locatelli F; Minutolo R; De Nicola L; Del Vecchio L
Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
Packer M
Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Therapy for Anemia in Renal Transplantation Patients by Prior Erythropoiesis Stimulating Agent Use.
Nakamura N; Aso S; Nakagawa C; Tachibana M; Fujikawa A; Tsubouchi K; Gunge N; Miyazaki T; Okabe Y; Matsuzaki H; Matsuoka H; Haga N
Transplant Proc; 2023 May; 55(4):829-831. PubMed ID: 37105829
[TBL] [Abstract][Full Text] [Related]
36. Roxadustat: Do we know all the answers?
Li QY; Xiong QW; Yao X; Liu F; Tang X; Fu H; Tong T; Mao J; Peng WX
Biomol Biomed; 2023 May; 23(3):354-363. PubMed ID: 36724056
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?
Macdougall IC
Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):399-405. PubMed ID: 35894273
[TBL] [Abstract][Full Text] [Related]
38. Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia.
Li J; Haase VH; Hao CM
Kidney Dis (Basel); 2023 Jan; 9(1):1-11. PubMed ID: 36756084
[TBL] [Abstract][Full Text] [Related]
39. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis.
Zheng Q; Zhang P; Yang H; Geng Y; Tang J; Kang Y; Qi A; Li S
Heliyon; 2023 Apr; 9(4):e15310. PubMed ID: 37123954
[TBL] [Abstract][Full Text] [Related]
40. Association of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors with Cardiovascular Events and Death in Dialysis Patients: A Systematic Review and Meta-Analysis.
Guimarães MGM; Tapioca FPM; Neves FC; Moura-Neto JA; Passos LCS
Blood Purif; 2023; 52(7-8):721-728. PubMed ID: 37459846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
